Single LSD Dose Shows Promise in Reducing Anxiety for 12 Weeks

Phase 3 clinical trial results announced by Definium Therapeutics indicate that a pharmaceutical formulation of LSD may effectively alleviate generalized anxiety disorder symptoms for up to twelve weeks following a single administration. This finding builds on earlier phase 2b data published in JAMA, expanding the evidence base for psychedelic-assisted therapeutic approaches. The results suggest potential for developing novel anxiety treatments with sustained effects from a single dose. This research represents significant progress in exploring alternative pharmacological options for patients with generalized anxiety disorder who may not respond adequately to conventional medications.